Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Mirecule Expands Strategic FSHD Collaboration with Sanofi

March 18, 2026 at 07:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration focuses on delivering transformative treatments for patients with Facioscapulohumeral Muscular Dystrophy (FSHD).

Building upon the companies’ successful partnership in developing ARC therapies, the expanded agreement will facilitate the advancement of a best-in-class ARC aimed at suppressing DUX4, the genetic driver of this debilitating muscular disease.

Sanofi will continue to contribute its expertise in rare disease drug development and will remain responsible for downstream clinical development and global commercialization.

Dr. Anthony Saleh, CEO of Mirecule, stated, “The expanded collaboration allows us to bring forward the optimal disease-modifying therapy for clinical advancement that meets the preclinical milestones established at the beginning of our partnership.”

Mirecule is strongly committed to developing a treatment for FSHD, working closely with the patient community. The company looks forward to ongoing collaboration with the FSHD Society, Friends of FSH Research, and the NINDS SBIR program to bring its groundbreaking FSHD treatment to fruition.

About Mirecule:

Mirecule, Inc. is a biotechnology company focused on advancing next-generation RNA therapeutics for treating rare neuromuscular diseases. The company’s proprietary and validated Antibody RNA Conjugate (ARC) platform delivers RNA therapies that target and knock down disease-causing genes in muscle, addressing the underlying genetic causes of these disorders. Mirecule’s most advanced candidate, MC-DX4, has been in-licensed by Sanofi and is designed for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD), the third most common form of muscular dystrophy. Mirecule’s second program, MC-DNM2, targets Centronuclear Myopathy (CNM), a rare and devastating pediatric disease with no approved therapies. CNM often presents at birth, with a mortality rate of approximately 50% by age two. By targeting the underlying genetic drivers, Mirecule aims to deliver transformative therapies for patients suffering from these debilitating conditions, for which there are currently no treatments. For more information, please visit: www.mirecule.com .